Sodium-ion capacitors(SICs)have received increasing interest for grid stationary energy storage application due to their affordability,high power,and energy densities.The major challenge for SICs is to overcome the ki...Sodium-ion capacitors(SICs)have received increasing interest for grid stationary energy storage application due to their affordability,high power,and energy densities.The major challenge for SICs is to overcome the kinetics imbalance between faradaic anode and nonfaradaic cathode.To boost the Na+reaction kinetics,the present work demonstrated a high-rate MnS-based anode by embedding the MnS nanocrystals into the N,S-co-doped carbon matrix(MnS@NSC).Benefiting from the fast pseudocapacitive Na+storage behavior,the resulting composite exhibits extraordinary rate capability(205.6 mAh g−1 at 10 A g−1)and outstanding cycling stability without notable degradation after 2000 cycles.A prototype SIC was demonstrated using MnS@NSC anode and N-doped porous carbon(NC)cathode;the obtained hybrid SIC device can display a high energy density of 139.8 Wh kg−1 and high power density of 11,500 W kg−1,as well as excellent cyclability with 84.5%capacitance retention after 3000 cycles.The superior electrochemical performance is contributed to downsizing of MnS and encapsulation of conductive N,S-co-doped carbon matrix,which not only promote the Na+and electrons transport,but also buffer the volume variations and maintain the structure integrity during Na+insertion/extraction,enabling its comparable fast reaction kinetics and cyclability with NC cathode.展开更多
目的系统评价钠—葡萄糖协同转运蛋白-2抑制剂(SGLT2i)治疗2型糖尿病的有效性和安全性。方法计算机检索PubMed、Cochrane Library、Embase、Web of Science及中国知网、万方数据知识服务平台上公开发表的SGLT2i治疗2型糖尿病患者有效性...目的系统评价钠—葡萄糖协同转运蛋白-2抑制剂(SGLT2i)治疗2型糖尿病的有效性和安全性。方法计算机检索PubMed、Cochrane Library、Embase、Web of Science及中国知网、万方数据知识服务平台上公开发表的SGLT2i治疗2型糖尿病患者有效性及安全性的随机对照试验(RCTs),文献检索时限从建库至2022年5月1日。对照组给予安慰剂治疗,试验组给予SGLT2i治疗。根据Cochrane偏倚风险评价工具对纳入文献进行质量评价,采用RevMan 5.3软件和Stata软件进行Meta分析。结果最终纳入5篇文献,共包含40205例患者,文献整体质量较高。Meta分析结果显示,与对照组相比,试验组心血管死亡或首次心力衰竭住院风险[HR=0.75,95%CI(0.61,0.92),P=0.005]、首次心力衰竭住院风险[HR=0.70,95%CI(0.60,0.82),P<0.001]显著降低,但2组心血管死亡风险[HR=0.99,95%CI(0.84,1.16),P=0.86]、全因死亡风险[HR=0.92,95%CI(0.83,1.01),P=0.09]、严重不良反应发生率[HR=1.01,95%CI(0.93,1.09),P=0.84]、急性损伤发生率[HR=0.84,95%CI(0.63,1.12),P=0.24]比较差异无统计学意义。Egger检验结果显示,报道心血管死亡或首次心力衰竭住院风险、首次心力衰竭住院风险的文献无明显发表偏倚(P值分别为0.22、0.37)。结论基于现有证据表明,SGLT2i可降低2型糖尿病患者心血管死亡或首次心力衰竭住院综合风险和首次心力衰竭住院风险,且无严重不良反应和急性肾损伤发生。展开更多
基金financially supported by the NRF Investigatorship (NRFI), Award No. NRF-NRFI2016-05the Campus for Research Excellent and Technological Enterprise (CREATE),National Research Foundation, Prime Minister’s Office, Singapore
文摘Sodium-ion capacitors(SICs)have received increasing interest for grid stationary energy storage application due to their affordability,high power,and energy densities.The major challenge for SICs is to overcome the kinetics imbalance between faradaic anode and nonfaradaic cathode.To boost the Na+reaction kinetics,the present work demonstrated a high-rate MnS-based anode by embedding the MnS nanocrystals into the N,S-co-doped carbon matrix(MnS@NSC).Benefiting from the fast pseudocapacitive Na+storage behavior,the resulting composite exhibits extraordinary rate capability(205.6 mAh g−1 at 10 A g−1)and outstanding cycling stability without notable degradation after 2000 cycles.A prototype SIC was demonstrated using MnS@NSC anode and N-doped porous carbon(NC)cathode;the obtained hybrid SIC device can display a high energy density of 139.8 Wh kg−1 and high power density of 11,500 W kg−1,as well as excellent cyclability with 84.5%capacitance retention after 3000 cycles.The superior electrochemical performance is contributed to downsizing of MnS and encapsulation of conductive N,S-co-doped carbon matrix,which not only promote the Na+and electrons transport,but also buffer the volume variations and maintain the structure integrity during Na+insertion/extraction,enabling its comparable fast reaction kinetics and cyclability with NC cathode.
文摘目的系统评价钠—葡萄糖协同转运蛋白-2抑制剂(SGLT2i)治疗2型糖尿病的有效性和安全性。方法计算机检索PubMed、Cochrane Library、Embase、Web of Science及中国知网、万方数据知识服务平台上公开发表的SGLT2i治疗2型糖尿病患者有效性及安全性的随机对照试验(RCTs),文献检索时限从建库至2022年5月1日。对照组给予安慰剂治疗,试验组给予SGLT2i治疗。根据Cochrane偏倚风险评价工具对纳入文献进行质量评价,采用RevMan 5.3软件和Stata软件进行Meta分析。结果最终纳入5篇文献,共包含40205例患者,文献整体质量较高。Meta分析结果显示,与对照组相比,试验组心血管死亡或首次心力衰竭住院风险[HR=0.75,95%CI(0.61,0.92),P=0.005]、首次心力衰竭住院风险[HR=0.70,95%CI(0.60,0.82),P<0.001]显著降低,但2组心血管死亡风险[HR=0.99,95%CI(0.84,1.16),P=0.86]、全因死亡风险[HR=0.92,95%CI(0.83,1.01),P=0.09]、严重不良反应发生率[HR=1.01,95%CI(0.93,1.09),P=0.84]、急性损伤发生率[HR=0.84,95%CI(0.63,1.12),P=0.24]比较差异无统计学意义。Egger检验结果显示,报道心血管死亡或首次心力衰竭住院风险、首次心力衰竭住院风险的文献无明显发表偏倚(P值分别为0.22、0.37)。结论基于现有证据表明,SGLT2i可降低2型糖尿病患者心血管死亡或首次心力衰竭住院综合风险和首次心力衰竭住院风险,且无严重不良反应和急性肾损伤发生。
